{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,7]],"date-time":"2025-08-07T20:57:12Z","timestamp":1754600232205},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2023,7,30]],"date-time":"2023-07-30T00:00:00Z","timestamp":1690675200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,7,30]],"date-time":"2023-07-30T00:00:00Z","timestamp":1690675200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1245\/s10434-023-13968-5","type":"journal-article","created":{"date-parts":[[2023,7,29]],"date-time":"2023-07-29T23:02:17Z","timestamp":1690671737000},"page":"7206-7216","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Time Trend Analysis of Splenectomy for Splenic Marginal Zone Lymphoma: Declining Surgery, Promising Survival"],"prefix":"10.1245","volume":"30","author":[{"given":"Zhen","family":"Yang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lianshuang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kaiming","family":"Leng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guangjun","family":"Shi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,7,30]]},"reference":[{"key":"13968_CR1","unstructured":"Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW. WHO classification of tumours of haematopoietic and lymphoid tissues, vol. 2: International Agency for Research on Cancer Lyon; 2008."},{"issue":"12","key":"13968_CR2","doi-asserted-by":"publisher","first-page":"4643","DOI":"10.1182\/blood-2005-11-4659","volume":"107","author":"L Arcaini","year":"2006","unstructured":"Arcaini L, Lazzarino M, Colombo N, Burcheri S, Boveri E, Paulli M, Morra E, Gambacorta M, Cortelazzo S, Tucci A, Ungari M, Ambrosetti A, Menestrina F, Orsucci L, Novero D, Pulsoni A, Frezzato M, Gaidano G, Vallisa D, Minardi V, Tripodo C, Callea V, Baldini L, Merli F, Federico M, Franco V, Iannitto E. Splenic marginal zone lymphoma: A prognostic model for clinical use. Blood. 2006;107(12):4643\u20139.","journal-title":"Blood."},{"issue":"3","key":"13968_CR3","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1002\/cncr.27773","volume":"119","author":"AJ Olszewski","year":"2013","unstructured":"Olszewski AJ, Castillo JJ. Survival of patients with marginal zone lymphoma: Analysis of the Surveillance, Epidemiology, and End Results database. Cancer. 2013;119(3):629\u201338.","journal-title":"Cancer."},{"issue":"1","key":"13968_CR4","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1002\/cncr.21931","volume":"107","author":"AM Tsimberidou","year":"2006","unstructured":"Tsimberidou AM, Catovsky D, Schlette E, O\u2019Brien S, Wierda WG, Kantarjian H, Garcia-Manero G, Wen S, Do KA, Lerner S, Keating MJ. Outcomes in patients with splenic marginal zone lymphoma and marginal zone lymphoma treated with rituximab with or without chemotherapy or chemotherapy alone. Cancer. 2006;107(1):125\u201335.","journal-title":"Cancer."},{"issue":"6","key":"13968_CR5","first-page":"856","volume":"90","author":"M Bennett","year":"2005","unstructured":"Bennett M, Sharma K, Yegena S, Gavish I, Dave HP, Schechter GP. Rituximab monotherapy for splenic marginal zone lymphoma. Haematologica. 2005;90(6):856\u20138.","journal-title":"Haematologica."},{"issue":"3","key":"13968_CR6","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1002\/hon.820","volume":"25","author":"C Kalpadakis","year":"2007","unstructured":"Kalpadakis C, Pangalis GA, Dimopoulou MN, Vassilakopoulos TP, Kyrtsonis MC, Korkolopoulou P, Kontopidou FN, Siakantaris MP, Dimitriadou EM, Kokoris SI, Tsaftaridis P, Plata E, Angelopoulou MK. Rituximab monotherapy is highly effective in splenic marginal zone lymphoma. Hematol Oncol. 2007;25(3):127\u201331.","journal-title":"Hematol Oncol."},{"key":"13968_CR7","doi-asserted-by":"crossref","unstructured":"Dreyling M, Thieblemont C, Gallamini A, Arcaini L, Campo E, Hermine O, Kluin-Nelemans JC, Ladetto M, Le Gouill S, Iannitto E, Pileri S, Rodriguez J, Schmitz N, Wotherspoon A, Zinzani P, Zucca E. ESMO Consensus conferences: guidelines on malignant lymphoma. part 2: marginal zone lymphoma, mantle cell lymphoma, peripheral T-cell lymphoma. Ann Oncol. 2013;24(4):857\u201377.","DOI":"10.1093\/annonc\/mds643"},{"issue":"2","key":"13968_CR8","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1053\/j.seminhematol.2010.01.004","volume":"47","author":"M Bennett","year":"2010","unstructured":"Bennett M, Schechter GP. Treatment of splenic marginal zone lymphoma: Splenectomy versus rituximab. Sem Hematol. 2010;47(2):143\u20137.","journal-title":"Sem Hematol."},{"issue":"7","key":"13968_CR9","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.3109\/10428194.2013.845884","volume":"55","author":"C Kalpadakis","year":"2014","unstructured":"Kalpadakis C, Pangalis GA, Vassilakopoulos TP, Sachanas S, Angelopoulou MK. Treatment of splenic marginal zone lymphoma: Should splenectomy be abandoned? Leukemia Lymphoma. 2014;55(7):1463\u201370.","journal-title":"Leukemia Lymphoma."},{"issue":"2","key":"13968_CR10","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.clml.2014.07.002","volume":"15","author":"C Tarella","year":"2015","unstructured":"Tarella C, Arcaini L, Baldini L, Barosi G, Billio A, Marchetti M, Rambaldi A, Vitolo U, Zinzani PL, Tura S. Italian Society of Hematology, Italian Society of Experimental Hematology, and Italian Group for Bone Marrow Transplantation guidelines for the management of indolent, nonfollicular B-cell lymphoma (marginal zone, lymphoplasmacytic, and small lymphocytic lymphoma). Clin Lymph Myeloma Leukemia. 2015;15(2):75\u201385.","journal-title":"Clin Lymph Myeloma Leukemia."},{"issue":"7","key":"13968_CR11","doi-asserted-by":"publisher","first-page":"1380","DOI":"10.3109\/10428194.2012.743655","volume":"54","author":"L Liu","year":"2013","unstructured":"Liu L, Wang H, Chen Y, Rustveld L, Liu G, Du XL. Splenic marginal zone lymphoma: a population-based study on the 2001\u20132008 incidence and survival in the United States. Leukemia Lymph. 2013;54(7):1380\u20136.","journal-title":"Leukemia Lymph."},{"key":"13968_CR12","doi-asserted-by":"crossref","unstructured":"Montalb\u00e1n C, Abraira V, Arcaini L, Domingo\u2010Domenech E, Guisado\u2010Vasco P, Iannito E, Mollejo M, Matutes E, Ferreri A, Salar AJBjoh. Risk stratification for Splenic Marginal Zone Lymphoma based on haemoglobin concentration, platelet count, high lactate dehydrogenase level and extrahilar lymphadenopathy: Development and validation on 593 cases. 2012;159(2):164\u201371.","DOI":"10.1111\/bjh.12011"},{"issue":"8","key":"13968_CR13","doi-asserted-by":"publisher","first-page":"1854","DOI":"10.3109\/10428194.2013.861067","volume":"55","author":"J Lenglet","year":"2014","unstructured":"Lenglet J, Traull\u00e9 C, Mounier N, Benet C, Munoz-Bongrand N, Amorin S, Noguera ME, Traverse-Glehen A, French M, Baseggio L, Felman P, Callet-Bauchu E, Brice P, Berger F, Salles G, Bri\u00e8re J, Coiffier B, Thieblemont C. Long-term follow-up analysis of 100 patients with splenic marginal zone lymphoma treated with splenectomy as first-line treatment. Leukemia Lymphoma. 2014;55(8):1854\u201360.","journal-title":"Leukemia Lymphoma."},{"key":"13968_CR14","doi-asserted-by":"crossref","unstructured":"Troussard X, Valensi F, Duchayne E, Garand R, Felman P, Tulliez M, Henry-Amar M, Bryon PA, Flandrin G. Splenic lymphoma with villous lymphocytes: Clinical presentation, biology and prognostic factors in a series of 100 patients. Groupe Francais d'H\u00e9matologie Cellulaire (GFHC). Br J Haematol. 1996;93(3):731-6.","DOI":"10.1046\/j.1365-2141.1996.d01-1711.x"},{"issue":"3","key":"13968_CR15","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1111\/bjh.12036","volume":"159","author":"M Else","year":"2012","unstructured":"Else M, Mar\u00edn-Niebla A, de la Cruz F, Batty P, R\u00edos E, Dearden CE, Catovsky D, Matutes E. Rituximab, used alone or in combination, is superior to other treatment modalities in splenic marginal zone lymphoma. Br J Haematol. 2012;159(3):322\u20138.","journal-title":"Br J Haematol."},{"issue":"5","key":"13968_CR16","doi-asserted-by":"publisher","first-page":"1648","DOI":"10.1182\/blood.V100.5.1648.h81702001648_1648_1654","volume":"100","author":"JI Chac\u00f3n","year":"2002","unstructured":"Chac\u00f3n JI, Mollejo M, Mu\u00f1oz E, Algara P, Mateo M, Lopez L, Andrade J, Carbonero IG, Mart\u00ednez B, Piris MA, Cruz MA. Splenic marginal zone lymphoma: Clinical characteristics and prognostic factors in a series of 60 patients. Blood. 2002;100(5):1648\u201354.","journal-title":"Blood."},{"issue":"4","key":"13968_CR17","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1111\/bjh.13320","volume":"169","author":"KH Xing","year":"2015","unstructured":"Xing KH, Kahlon A, Skinnider BF, Connors JM, Gascoyne RD, Sehn LH, Savage KJ, Slack GW, Shenkier TN, Klasa R, Gerrie AS, Villa D. Outcomes in splenic marginal zone lymphoma: analysis of 107 patients treated in British Columbia. Br J Haematol. 2015;169(4):520\u20137.","journal-title":"Br J Haematol."},{"issue":"3","key":"13968_CR18","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1111\/bjh.17577","volume":"194","author":"A Sima","year":"2021","unstructured":"Sima A, Hollander P, Baecklund E, Smedby KE, Enblad G, Amini RM. Superior outcome for splenectomised patients in a population-based study of splenic marginal zone lymphoma in Sweden. Br J Haematol. 2021;194(3):568\u201379.","journal-title":"Br J Haematol."},{"key":"13968_CR19","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.leukres.2016.03.005","volume":"44","author":"S Perrone","year":"2016","unstructured":"Perrone S, D\u2019Elia GM, Annechini G, Ferretti A, Tosti ME, Fo\u00e0 R, Pulsoni A. Splenic marginal zone lymphoma: Prognostic factors, role of watch and wait policy, and other therapeutic approaches in the rituximab era. Leukemia Res. 2016;44:53\u201360.","journal-title":"Leukemia Res."},{"issue":"3","key":"13968_CR20","doi-asserted-by":"publisher","first-page":"276.e271","DOI":"10.1016\/j.amjmed.2005.07.044","volume":"119","author":"MH Kyaw","year":"2006","unstructured":"Kyaw MH, Holmes EM, Toolis F, Wayne B, Chalmers J, Jones IG, Campbell H. Evaluation of severe infection and survival after splenectomy. Am J Med. 2006;119(3):276.e271-7.","journal-title":"Am J Med."},{"issue":"1","key":"13968_CR21","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.beha.2017.10.011","volume":"31","author":"C Kalpadakis","year":"2018","unstructured":"Kalpadakis C, Pangalis GA, Angelopoulou MK, Sachanas S, Vassilakopoulos TP. Should rituximab replace splenectomy in the management of splenic marginal zone lymphoma? Best Pract Res Clin Haematol. 2018;31(1):65\u201372.","journal-title":"Best Pract Res Clin Haematol."},{"issue":"1","key":"13968_CR22","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.annonc.2019.10.010","volume":"31","author":"E Zucca","year":"2020","unstructured":"Zucca E, Arcaini L, Buske C, Johnson PW, Ponzoni M, Raderer M, Ricardi U, Salar A, Stamatopoulos K, Thieblemont C, Wotherspoon A, Ladetto M. Marginal zone lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2020;31(1):17\u201329.","journal-title":"Ann Oncol."},{"key":"13968_CR23","doi-asserted-by":"crossref","unstructured":"Florindez JA, Alderuccio JP, Reis IM, Lossos IS. Splenic marginal zone lymphoma: A U.S. population-based survival analysis (1999\u20132016). Cancer. 2020;126(21):4706\u201316.","DOI":"10.1002\/cncr.33117"},{"issue":"3","key":"13968_CR24","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1007\/s00277-013-1900-4","volume":"93","author":"AJ Olszewski","year":"2014","unstructured":"Olszewski AJ, Ali S. Comparative outcomes of rituximab-based systemic therapy and splenectomy in splenic marginal zone lymphoma. Ann Hematol. 2014;93(3):449\u201358.","journal-title":"Ann Hematol."},{"issue":"2","key":"13968_CR25","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1634\/theoncologist.2012-0251","volume":"18","author":"C Kalpadakis","year":"2013","unstructured":"Kalpadakis C, Pangalis GA, Angelopoulou MK, Sachanas S, Kontopidou FN, Yiakoumis X, Kokoris SI, Dimitriadou EM, Dimopoulou MN, Moschogiannis M, Korkolopoulou P, Kyrtsonis MC, Siakantaris MP, Papadaki T, Tsaftaridis P, Plata E, Papadaki HE, Vassilakopoulos TP. Treatment of splenic marginal zone lymphoma with rituximab monotherapy: Progress report and comparison with splenectomy. Oncologist. 2013;18(2):190\u20137.","journal-title":"Oncologist."},{"issue":"2","key":"13968_CR26","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1002\/1097-0142(20010115)91:2<294::AID-CNCR1001>3.0.CO;2-W","volume":"91","author":"V Franco","year":"2001","unstructured":"Franco V, Florena AM, Stella M, Rizzo A, Iannitto E, Quintini G, Campesi G. Splenectomy influences bone marrow infiltration in patients with splenic marginal zone cell lymphoma with or without villous lymphocytes. Cancer. 2001;91(2):294\u2013301.","journal-title":"Cancer."}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-023-13968-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-023-13968-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-023-13968-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,9]],"date-time":"2023-10-09T19:09:09Z","timestamp":1696878549000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1245\/s10434-023-13968-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,30]]},"references-count":26,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2023,11]]}},"alternative-id":["13968"],"URL":"https:\/\/doi.org\/10.1245\/s10434-023-13968-5","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,30]]},"assertion":[{"value":"2 May 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 July 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 July 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}